Last reviewed · How we verify
GW685698X
GW685698X is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
GW685698X is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | GW685698X |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it potentially useful in chronic inflammatory airway diseases. The selective PDE4 inhibition aims to provide anti-inflammatory benefits while minimizing systemic side effects associated with non-selective phosphodiesterase inhibition.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
- Study of GW685698X In Patients With Seasonal Allergic Rhinitis (PHASE3)
- A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy. (PHASE2)
- Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR) (PHASE3)
- Study Of Adults And Adolescents With Vasomotor Rhinitis (PHASE3)
- A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma. (PHASE2)
- Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function (PHASE1)
- A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy. (PHASE2)
- Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |